Trials / Terminated
TerminatedNCT04517253
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of baricitinib in adult and pediatric Japanese participants with Nakajo-Nishimura Syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS/CANDLE), STING-associated vasculopathy with onset during infancy (SAVI), and Aicardi-Goutières Syndrome (AGS).
Conditions
- Nakajo-Nishimura Syndrome
- Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome
- STING-Associated Vasculopathy With Onset in Infancy
- Aicardi Goutieres Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | Administered orally |
Timeline
- Start date
- 2020-10-27
- Primary completion
- 2023-04-04
- Completion
- 2024-11-28
- First posted
- 2020-08-18
- Last updated
- 2025-07-10
- Results posted
- 2022-12-21
Locations
5 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04517253. Inclusion in this directory is not an endorsement.